Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.36 |
| ▸ | CACNA1I | Q9P0X4 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.35 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23568463 | 0.84 | L3MBTL1 (0.44) | PIK3CDKDM4EALDH1A1TDP1CYP2D6 | |
| SCHEMBL22856529 | 0.82 | KDM4E (0.39) | PIK3CDKDM4EALDH1A1TDP1CYP2D6 | |
| SCHEMBL23841859 | 0.81 | KCNH2 (0.40) | PIK3CDKDM4EALDH1A1TDP1CYP2D6 | |
| SCHEMBL25691521 | 0.79 | PIK3CD (0.43) | PIK3CDKDM4EALDH1A1TDP1CYP2D6 | |
| SCHEMBL21107430 | 0.79 | PIK3CD (0.43) | PIK3CDKDM4EALDH1A1TDP1CYP2D6 | |
| SCHEMBL25828843 | 0.78 | CYP2D6 (0.46) | PIK3CDALDH1A1CYP2D6SMN1; SMN2 | |
| SCHEMBL1687229 | 0.77 | PIK3CD (0.42) | PIK3CDKDM4EALDH1A1TDP1CYP2D6 | |
| SCHEMBL1621207 | 0.77 | PIK3CD (0.42) | PIK3CDKDM4EALDH1A1TDP1CYP2D6 | |
| SCHEMBL13683795 | 0.75 | PIK3CD (0.44) | PIK3CDKDM4EALDH1A1TDP1CYP2D6 | |
| SCHEMBL599158 | 0.75 | NCF1 (0.52) | PIK3CDKDM4EALDH1A1TDP1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234953-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234953-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | PIK3CD 321/4885KDM4E 190/4885ALDH1A1 2776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.